Dr. Engelman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yaw 7
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-278-6995
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2002
Albert Einstein College of MedicineClass of 2000
Certifications & Licensure
MA State Medical License 2003 - 2022
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Clinical Trials
- BKM120 in Cancers With PIK3CA Activating Mutations Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- 829 citationsCaveolins, liquid-ordered domains, and signal transduction.Eric J. Smart, Gregory A. Graf, Mark A. McNiven, William C. Sessa, Jeffrey A. Engelman
Molecular and Cellular Biology. 1999-11-01 - 391 citationsGenomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A. Margolis, Natalie I. Vokes, David Liu, Amaro Taylor-Weiner
Nature Genetics. 2018-08-27 - 303 citationsSynthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi
Cancer Cell. 2013-01-14
Journal Articles
- Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic LeukemiaJohn E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature
- Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid TumorsJeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
Press Mentions
JAMA Study Shows Pharma Companies Struggle to Meet Postapproval Study DeadlinesOctober 6th, 2022
Evaluating First-Line Ceritinib Therapy in ALK-Rearranged NSCLC PatientsSeptember 13th, 2017
Brain Microenvironment Makes HER2-Positive Breast Cancer Metastases Resistant to TreatmentMay 24th, 2017- Join now to see all
Grant Support
- Identification Of Resistance Mechanisms To Anaplastic Lymphoma Kinase InhibitorsNational Cancer Institute2012
- The Activation Of ERBB3 Signaling As A Resistance Mechanism To Targeted TherapiesNational Cancer Institute2009–2012
- Inhibition Of P13K And MEK Pathways In The Treatment Of Lung CancerNational Cancer Institute2009–2011
- Molecular Mechanisms Of PI3K Activation In Non-Small Cell Lung CancerNational Cancer Institute2006–2010
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
